Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2025 13:00 ET | Source: DelveInsight Business Research LLP

CAR-TCR Summit Coverage – Track Latest Insights on Novel CAR-T Cell Therapies for B-Cell Malignancies | DelveInsight

New York, USA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- CAR-TCR Summit Coverage – Track Latest Insights on Novel CAR-T Cell Therapies for B-Cell Malignancies | DelveInsight A case study on how...
July 18, 2016 16:00 ET | Source: ArQule, Inc.

ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference

Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today...
May 26, 2011 08:30 ET | Source: Semafore Pharmaceuticals

Semafore Pharmaceuticals to Present SF1126 Clinical Data at ASCO Annual Meeting

INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of...
March 09, 2011 07:30 ET | Source: Semafore Pharmaceuticals

Semafore Pharmaceuticals Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting

INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals announced today that preclinical data in B-cell malignancies for the company's lead product candidate SF1126 will be presented...